Government Shutdown Poised to Become Longest in U.S. History

美国政府关门危机有望成为美国历史上最长的关门事件

WSJ What’s News

2025-11-05

12 分钟
PDF

单集简介 ...

P.M. Edition for Nov. 4. WSJ’s Congress reporter Katy Stech Ferek talks about the latest in negotiations as lawmakers search for a deal to end the shutdown. Spencer Jakab, who writes WSJ’s Markets A.M. newsletter, explains why a famous method of valuing stocks suggests rough years ahead. And it’s Election Day in the U.S. Head to WSJ’s live blog for more coverage of key races in New York City, New Jersey and Virginia. Sabrina Siddiqui hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
更多

单集文稿 ...

  • The government shutdown nears a record as the longest in U.S.

  • history.

  • Plus,

  • what an ominous milestone for a famous method of valuing stocks tells us about what's next for markets.

  • It's proven to be an extremely reliable indicator of what to expect in the several years ahead of us.

  • And former Vice President Dick Cheney, an architect of the U.S.

  • War on Terror, has died at 84.

  • It's Tuesday, November 4th.

  • I'm Sabrina Sidiki for The Wall Street Journal, sitting in for Alex Osala.

  • This is the PM edition of What's News,

  • the top headlines and business stories that move the world today.

  • The Trump administration is negotiating with Eli Lilly and Novo Nordisk to offer their blockbuster weight loss drugs at lower prices as low as $149 for a month's supply through a Trump-branded government website

  • for buying medications.

  • People familiar with the matter say the proposed agreements would also mean Medicare and Medicaid coverage of expensive obesity drugs like Wigowi and Zepbound.

  • Medicare drug benefit plans today can cover the weight loss drugs just not only for losing weight.

  • For example, they're available for reducing risk of heart attacks or sleep apnea.

  • And few states offer Medicaid coverage for the drugs for weight loss.

  • And that's not the only news today about the weight loss drug market.

  • There's a new twist in the high stakes bidding war for the obesity drug developer Metzera as Novo Nordisk and Pfizer have both raised their offers for the company.

  • Metzera said today that Novo Nordisk's proposal values the company at approximately $10 billion,